Pharmaceutical Technology on MSN
Recursion CEO details novel Phase III endpoint for rare disease drug
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
JetBrains' 2026 developer survey puts Python ahead of JavaScript, with TypeScript leading growth potential and Rust topping ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
A hands-on benchmark comparing AWS Amplify, Lambda, Web Functions, and ECS for Next.js, covering latency, cold starts, ...
Learn how to make your docs AI-readable with llms.txt, llms-full.txt, clean Markdown, and semantic structure, so AI tools and ...
Anthropic has added Code Mode to Claude Code as an experimental, opt-in feature. Claude Code Code Mode is a mode in which ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.10 since the market last closed. This is a 3.72% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results